D. Nosov

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

Jens Bedke, Brian I. Rini, Elizabeth R. Plimack et al. · European Urology · 2022 · 32 citations

Urology, Life Analysis, Axitinib Versus Sunitinib +7

Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

Pankaj Bhargava, B. Esteves, Mohammed Al-Adhami et al. · Journal of Clinical Oncology · 2010 · 24 citations

Surgical Oncology, Renal Pathology, Pharmacotherapy +19

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

Robert J. Motzer, D. Nosov, Tim Eisen et al. · European Urology Supplements · 2012 · 19 citations

Urology, Genitourinary Cancer, Medicine +7

Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC).

D. Nosov, Pankaj Bhargava, W. B. Esteves et al. · Journal of Clinical Oncology · 2011 · 19 citations

Surgical Oncology, Pharmacotherapy, Oncology +18

Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).

Bernard Escudier, Robert J. Motzer, Thomas Powles et al. · Journal of Clinical Oncology · 2016 · 15 citations

Preclinical Therapeutics, Pharmacotherapy, Molecular Pharmacology +19